share_log

中國生物製藥：截至二零二四年四月三十日止月份的股份發行人的證券變動月報表

SINO BIOPHARM: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024

Hong Kong Stock Exchange ·  May 5 22:37
Summary by Moomoo AI
中國生物製藥有限公司於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，維持在30,000,000,000股，每股面值0.025港元，總股本為750,000,000港元。此外，公司的股份期權計劃及可換股票據在本月內亦無變動，並無新股份發行。公司秘書陳凱年確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
中國生物製藥有限公司於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，維持在30,000,000,000股，每股面值0.025港元，總股本為750,000,000港元。此外，公司的股份期權計劃及可換股票據在本月內亦無變動，並無新股份發行。公司秘書陳凱年確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
China Biopharmaceuticals Limited filed with Hong Kong Trading and Settlement Limited on 6 May 2024 with Hong Kong Trading and Settlement Holdings Limited, reporting the changes in the company's shares for the year ended 30 April 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged during the month at 30,000,000,000 shares with a face value of HK$0.025 per share and a total share capital of HK$750,000,000. In addition, the Company's stock option plan and convertible notes were unchanged during the month and no new shares were issued. COMPANY SECRETARY CHAN KAI NEN CONFIRMED THAT ALL SECURITIES ISSUANCE HAD BEEN AUTHORISED BY THE BOARD OF DIRECTORS AND COMPLIED WITH THE RELEVANT REQUIREMENTS OF THE SECURITIES LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.
China Biopharmaceuticals Limited filed with Hong Kong Trading and Settlement Limited on 6 May 2024 with Hong Kong Trading and Settlement Holdings Limited, reporting the changes in the company's shares for the year ended 30 April 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged during the month at 30,000,000,000 shares with a face value of HK$0.025 per share and a total share capital of HK$750,000,000. In addition, the Company's stock option plan and convertible notes were unchanged during the month and no new shares were issued. COMPANY SECRETARY CHAN KAI NEN CONFIRMED THAT ALL SECURITIES ISSUANCE HAD BEEN AUTHORISED BY THE BOARD OF DIRECTORS AND COMPLIED WITH THE RELEVANT REQUIREMENTS OF THE SECURITIES LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more